Real-World Tumor Response of Palbociclib plus Letrozole versus Letrozole for Metastatic Breast Cancer in US Clinical Practice

2021 Year in Review - HER2-Negative Breast Cancer —January 21, 2022

Categories:

Breast Cancer

The objective of this study was to compare the real-world tumor response of palbociclib plus the aromatase inhibitor letrozole versus letrozole alone in patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer in the United States.1

Using the Flatiron Health Analytics database, procedures and patients with HR-positive, HER2-negative metastatic breast cancer who received palbociclib plus letrozole or letrozole monotherapy as first-line treatment between February 2015 and September 2018 were included in this retrospective research. Patients were followed up through December 2018. The best tumor response in the real world was calculated using physicians’ assessments of radiologic evidence for changes in disease burden.1

Approximately 70% of the 1383 eligible patients who received the palbociclib plus letrozole combination (N = 662) or letrozole monotherapy (N = 306) as first-line therapy had ≥1 tumor response evaluations. In the first-line scenario, the real-world best tumor response rate (full response plus partial response) was 59.8% in the palbociclib plus letrozole group and 39.2% in the letrozole monotherapy group (P <.0001). The real-world best tumor response rate in the palbociclib plus letrozole group was 58.6% versus 39.1% in the letrozole group after 1:1 propensity score matching.1

In this large cohort of general oncology practice patients in the United States, patients with HR-positive, HER2-negative metastatic breast cancer treated with first-line palbociclib plus letrozole had a considerably higher likelihood of tumor response than those treated with letrozole alone. Furthermore, when compared with letrozole alone, treatment with first-line palbociclib plus letrozole resulted in significant improvements in real-world progression-free survival and overall survival.1

These findings support palbociclib plus letrozole as a standard-of-care treatment for patients with HR-positive, HER2-negative metastatic breast cancer, and they add to the therapeutic benefit shown with palbociclib plus endocrine therapy in randomized clinical studies.1

Reference

  1. Brufsky A, Liu X, Li B, et al. Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice. Target Oncol. 2021;16:601-611. Erratum in: Target Oncol. 2021;16:865.
Related Articles
Breast Cancer Screening Among Women with Comorbidities: A Cross-Sectional Examination of Disparities from the Behavioral Risk Factor Surveillance System
Ashton Gatewood, MPH, BSN, RN, Mackenzie Enmeier, BS, Elise Stephenson, BA, Jordyn Austin, BS, Benjamin Greiner, DO, MPH, Micah Hartwell, PhD
|
June 2022 Vol 13, No 6
We found that people with co-occurring diagnoses including obesity, diabetes, hypertension, skin cancer, and arthritis completed breast cancer screening more often than those with no comorbidities. Conversely, individuals living with CVD, COPD, and depression were less likely to receive potentially lifesaving breast cancer screening, suggesting biases may be present in women with these diagnoses.
What AYAs with Breast Cancer and Their Providers Tell Us About Survivorship Needs
Heather Becker, PhD, Molly McAdam, MPH, Sharyn Malatok, MPA, Emily Croce, MSN, APRN, CPNP-PC, Eunju Choi, PhD, Elaine Gonzales, CN-BA, CHW, CHWI
|
April 2022 Vol 13, No 4
Sacituzumab Govitecan-hziy in the Treatment of HR-Positive Breast Cancer
2021 Year in Review - Triple-Negative Breast Cancer
Patients with endocrine-resistant HR-positive/HER2-negative metastatic breast cancer require novel therapeutic alternatives as a result of the poor outcomes of currently available later-line medications.
Last modified: January 21, 2022

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code